BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8542599)

  • 21. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
    Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
    Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
    J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation-induced DNA damage in tumors and normal tissues. I. Feasibility of estimating the hypoxic fraction.
    Zhang H; Wheeler KT
    Radiat Res; 1993 Oct; 136(1):77-88. PubMed ID: 8210342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.
    Evans SM; Hahn SM; Magarelli DP; Koch CJ
    Am J Clin Oncol; 2001 Oct; 24(5):467-72. PubMed ID: 11586098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
    Teicher BA; Holden SA; Ara G; Dupuis NP; Goff D
    Cancer J Sci Am; 1995; 1(1):43-8. PubMed ID: 9166453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
    Mahy P; De Bast M; Gallez B; Gueulette J; Koch CJ; Scalliet P; Grégoire V
    Radiother Oncol; 2003 Apr; 67(1):53-61. PubMed ID: 12758240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
    Evans SM; Judy KD; Dunphy I; Jenkins WT; Nelson PT; Collins R; Wileyto EP; Jenkins K; Hahn SM; Stevens CW; Judkins AR; Phillips P; Geoerger B; Koch CJ
    Cancer Res; 2004 Mar; 64(5):1886-92. PubMed ID: 14996753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion.
    Koch CJ; Oprysko PR; Shuman AL; Jenkins WT; Brandt G; Evans SM
    Cancer Res; 2002 Jul; 62(13):3626-9. PubMed ID: 12097264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
    Aboagye EO; Kelson AB; Tracy M; Workman P
    Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
    Salmon HW; Siemann DW
    Radiother Oncol; 2004 Dec; 73(3):359-66. PubMed ID: 15588883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing.
    Cárdenas-Navia LI; Yu D; Braun RD; Brizel DM; Secomb TW; Dewhirst MW
    Cancer Res; 2004 Sep; 64(17):6010-7. PubMed ID: 15342381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
    Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
    Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
    Evans SM; Schrlau AE; Chalian AA; Zhang P; Koch CJ
    J Invest Dermatol; 2006 Dec; 126(12):2596-606. PubMed ID: 16810299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia is important in the biology and aggression of human glial brain tumors.
    Evans SM; Judy KD; Dunphy I; Jenkins WT; Hwang WT; Nelson PT; Lustig RA; Jenkins K; Magarelli DP; Hahn SM; Collins RA; Grady MS; Koch CJ
    Clin Cancer Res; 2004 Dec; 10(24):8177-84. PubMed ID: 15623592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
    Busch TM; Hahn SM; Evans SM; Koch CJ
    Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
    Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.